Saniona appoints Rami Levin as President and Chief Executive Officer

pharmafile | January 8, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointments, rare diseases 

Saniona has announced that Rami Levin will take over as the Chief Executive Officer of the company as it seeks to transition into a fully-fledge biopharmaceuticals company, with a focus on rare diseases.

Levin was appointed by the Board of Directors and the company’s founders. His appointment takes immediate effect.

The Chairman of the Board, J. Donald deBethizy, said in a statement: “We are very excited to welcome Rami to Saniona as CEO, a role to which he brings years of highly relevant experience which will now underpin the continuing development of Saniona. Rami has a proven track record in a number of areas critical to Saniona, including rare diseases, the U.S. regulatory and market access environment and commercialization of innovative therapeutics, and are of increasing importance to the company as we seek to bring our highly promising products to markets.”

Rami Levin has over 23 years of experience in rare diseases and CNS. His most recent role was as the President of Sobi, and he led it through a period of ten-fold growth. Before joining Sobi, Levin had leadership roles at Merck Seron in a number of countries including Israel, the US, Sweden and Switzerland.

Commenting on his appointment, Levin said: “I am very proud to be taking on this tremendously exciting role with Saniona and overseeing the next stage in the company’s development. This is an important moment in the history of Saniona, as it aims to become a leading biotech company focusing on rare eating disorders and CNS diseases by developing new treatments that address significant unmet medical needs, both in-house and together with partners. As part of this, our focus in the near-term will be the development and commercial opportunity for Tesomet in the rare eating disorders Prader-Willi Syndrome (PWS) and in Hypothalamic Obesity (HO), particularly in the U.S.”

Levin holds a Bachelor’s degree in Biology and an MBA, majoring in International Marketing, both from Tel Aviv University in Israel. 

Related Content

Sanofi axes four major players from its executive committee

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …


Dr Richard Torbett is named as the new Chief Executive of the ABPI

The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …


Insys Therapeutics names current CFO Andrew Long as company’s new CEO

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …

Latest content